MA
FULC icon

MYDA Advisors’s Fulcrum Therapeutics FULC Stock Holding History

MYDA Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20,000
Closed -$354K – 230
2021
Q4 		$354K Buy
+20,000
New +$396K 0.09% 179

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MYDA Advisors's FULC Position: Q1 2025 in Review

MYDA Advisors sold out of Fulcrum Therapeutics (FULC) in Q1 2025, closing a stake of 63,970 shares — an estimated $301K sold.

MYDA Advisors first reported a position in FULC in Q1 2021 and held it in 6 quarters. The position peaked at $301K in Q4 2024. 117 funds tracked by Wall St. Rank hold FULC as of Q1 2025.

  • MYDA Advisors reported no remaining Fulcrum Therapeutics position as of Q1 2025 after selling out during the quarter.
  • MYDA Advisors sold 63,970 Fulcrum Therapeutics shares in Q1 2025, an estimated $301K.
  • MYDA Advisors first reported a position in Fulcrum Therapeutics in Q1 2021 and held it in 6 quarters.
  • MYDA Advisors's Fulcrum Therapeutics position peaked at $301K in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2025.

Based on MYDA Advisors's 13F filing for Q1 2025, filed 14 May 2025.